Inve India ▾

GlaxoSmithKline Pharmaceuticals share price & results

GlaxoSmithKline Pharmaceuticals Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

GSK India: biopharma maker of General Medicines, Vaccines and Specialty oncology/respiratory drugs.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue938 ₹ crore+16.5% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin31.0 %0.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit237 ₹ crore+15.6% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity49.93 %−1.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin22.76 %−11.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)5.75 %−6.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 5 judged targets kept · 6 open · verdicts reflect calls analysed to Q1 FY27.

GlaxoSmithKline Pharmaceuticals Limited management guidance track record on Inve: 11 targets tracked across analysed earnings calls (5 achieved, 0 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
New Product Launches (Oncology)Launch in either end of Q1 of the next year or earliest of Q1 of the next financial year or latest Q2.
Call transcript, Q3 FY25 · 14 Feb 2025		Q3 FY25Q1 FY27:Oncology portfolio (Zejula and Jemperli) is part of the innovation portfolio which contributed 7-7.5% to Q1 topline, impacting 260-270 patients.
Call transcript, Q1 FY27 · 3 Aug 2026		Achieved
Total RevenueDouble the business to INR 8,000 crores over the next 4-5 years (12-14% annual growth).
Call transcript, Q3 FY26 · 9 Feb 2026		Q3 FY26Q1 FY27:Management reaffirmed the INR 8,000 crore target over 4-5 years, requiring a 13-14% CAGR. Q1 reported growth was 15% YoY.
Call transcript, Q1 FY27 · 3 Aug 2026		On Track

Source: Inve Guidance Tracker for GlaxoSmithKline Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of GlaxoSmithKline Pharmaceuticals Limited's 11 targets are still open. See which are on track and which have gone quiet. The 2 above are the free sample; 9 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹2,445.9 +1.71% · +₹41.2

Last close 26 Oct 2026 · NSE · INR · Source: Inve

Performance −11.3% 1Y

₹2.2k₹2.4k₹2.6k₹2.8k₹3.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q3 FY26 — 9 Feb 2026Q4 FY26 — 13 May 2026Q1 FY27 — 3 Aug 2026

1Y: ₹2,758.1 on 24 Oct 2025 → ₹2,445.9. High ₹3,106.4 (28 Aug 2026), low ₹2,103.2 (11 Jun 2026).

Previous close
₹2,404.7
Market cap
₹41.8k Cr
52-week range
₹2,103.2 – ₹3,106.4
One year
−8.97%
Price to earnings (TTM to Jun 2026)
39.74×
Return on equity (TTM to Jun 2026)
49.93%

Overview

Symbol
NSE:GLAXO
Exchange
NSE
Currency
INR

What GlaxoSmithKline Pharmaceuticals Limited does

Based on the company's own presentations, annual report and earnings calls.

GlaxoSmithKline Pharmaceuticals is the Indian listed biopharma arm of GSK, discovering, developing and marketing prescription medicines and vaccines across three portfolios: General Medicines (anti-infectives, pain management, dermatology, hormones, vitamins/nutrition), Vaccines (paediatric and adult immunisation), and Specialty Medicines (respiratory and oncology). It earns by selling branded prescription drugs and vaccines through hospitals, stockists, trade and government-supply channels across India, manufactured largely at its own Nashik plant and supplemented by a network of contract manufacturers. The company is repositioning from its legacy General Medicines base toward a higher-growth innovation and specialty portfolio, including newly launched oncology and respiratory therapies and India's adult vaccination category (Shingrix).

Segments

  • General Medicines
  • Vaccines
  • Specialty Medicines
Manufacturing plant
1 (Nashik, Maharashtra)
Contract Manufacturing Organisations (CMOs) used
19 across India
Towns and cities in distribution network
1,400+
Stockists, hospitals, traders & government supply points
5,600+
Patients served in India (FY2025-26)
235+ Mn
Unit doses manufactured (FY2025-26)
9.8 Bn
Founded 1924Headquarters GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400030Employees 3,103 (FY2025-26) Company website

How the price took the results

close before → close after

Q1 FY27
+0.3%
3 Aug
Q4 FY26
−1.5%
13 May
Q3 FY26
+1.3%
9 Feb

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for GlaxoSmithKline Pharmaceuticals Limited

Free account: one company. Everything above stays public.

Write why you follow GlaxoSmithKline Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse GlaxoSmithKline Pharmaceuticals Limited

Guides on how to read this kind of business and the numbers that matter.